Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BLU 222

Next Previous
Drug Profile

BLU 222

Alternative Names: BLU-222

Latest Information Update: 09 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Blueprint Medicines
  • Class 1 ring heterocyclic compounds; 2 ring heterocyclic compounds; Amines; Antineoplastics; Ethers; Fluorocarbons; Pyrazines; Pyrazoles; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase I/II HER2 negative breast cancer; Solid tumours
  • Preclinical Ovarian cancer
  • No development reported Cancer; Gynaecological cancer

Most Recent Events

  • 09 Feb 2026 (NCT05252416) - Kdm, intro dev lines added and HE added
  • 28 Jan 2026 No recent reports of development identified for preclinical development in Gynaecological-cancer in USA
  • 24 Nov 2025 Blueprint Medicines Corporation terminates phase I/II VELA clinical trials in Solid tumours (Combination therapy, Monotherapy Second-line therapy or greater, Late-stage disease) in US, United Kingdom, Italy (PO), prior to the initiation of phase II for reasons not due to safety concerns (NCT05252416)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top